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INVITED COMMENTARYCommentary on ‘The Morphological Applicability of a Novel Endovascular
Aneurysm Sealing (EVAS) System (Nellix) in Patients with Abdominal Aortic
Aneurysms’
Y. Tshomba *, R. Chiesa
Scientiﬁc Institute H. San Raffaele, Milan, ItalyThe Nellix device introduces a fascinating new concept in
the ﬁeld of abdominal aortic aneurysm (AAA) endovascular
repair (EVR) independent from proximal and distal endog-
raft sealing and ﬁxation.
In the present issue of the European Journal of Vascular
and Endovascular Surgery, Karthikesalingam et al.1 reported
the rate of feasibility of EVR with Nellix in patients with AAA
who had undergone a variety of approaches. Overall 776
aneurysms were assessed for compliance with the In-
structions for Use (IFU) of Nellix and 70.1% were morpho-
logically suitable. In particular, 73.0% of the patients who
had undergone EVR were compliant with Nellix IFU, and this
rate was signiﬁcantly higher compared with that with the
IFU for the most common devices currently used in clinical
practice.
The main limitation of this interesting paper is, however,
its totally theoretical nature, Nellix being a really weakly
tested device. A preliminary experience of 20 cases has
been published by Kısis et al.2 with poorly documented data
about the sac behaviour. Donayre et al.3 reported in a more
detailed experience of 21 patients that the endograft was
successfully deployed with complete aneurysm exclusion in
all cases, even in those with associated common iliac artery
aneurysm. During a mean follow-up of 8.7  3.1 months,
there were no late aneurysm- or device-related adverse
events but two cases of type I endoleak were reported. This
experience was updated some months later with publica-
tion of a reviewed worldwide clinical experience with Core
Lab evaluation including 34 patients.4 Successful device
deployment was conﬁrmed in all patients, even in thoseDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2013.06.017
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cedure at 15 months. Follow-up CT scan extending up to 2
years revealed no change in aneurysm size or endograft
position and no new endoleaks.
In spite of the potential suitability for treatment within
the Nellix IFU of many patients who currently undergo EVR
outside the IFU, the experience with Nellix in the clinical
setting is inadequate. Larger series, longer follow-up and
careful clinical and technical outcomes assessment are
mandatory to understand whether potentially enlarged in-
dications go parallel with safety and effectiveness of the
current endovascular technology.REFERENCES
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